Drug Approval | October 04, 2024
Shilpa Pharma Lifesciences receives CEP from EDQM for API, Desmopressin
This is used to treat central diabetes insipidus and bedwetting
This is used to treat central diabetes insipidus and bedwetting
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The product is expected to be launched in Q3FY25
The inspection conducted by EDQM at its Visakhapatnam facility
Subscribe To Our Newsletter & Stay Updated
